AU2023245728A1 - Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof - Google Patents

Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof Download PDF

Info

Publication number
AU2023245728A1
AU2023245728A1 AU2023245728A AU2023245728A AU2023245728A1 AU 2023245728 A1 AU2023245728 A1 AU 2023245728A1 AU 2023245728 A AU2023245728 A AU 2023245728A AU 2023245728 A AU2023245728 A AU 2023245728A AU 2023245728 A1 AU2023245728 A1 AU 2023245728A1
Authority
AU
Australia
Prior art keywords
seq
bispecific antibody
sequence shown
domain
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023245728A
Other languages
English (en)
Inventor
Sung Hugh CHOI
Euijoon JEONG
Clemens REINSHAGEN
Anthony John ROSSOMANDO
Ho-Juhn Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pinetree Therapeutics Inc
Original Assignee
Pinetree Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinetree Therapeutics Inc filed Critical Pinetree Therapeutics Inc
Publication of AU2023245728A1 publication Critical patent/AU2023245728A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2023245728A 2022-03-30 2023-03-30 Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof Pending AU2023245728A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263325312P 2022-03-30 2022-03-30
US202263325317P 2022-03-30 2022-03-30
US63/325,312 2022-03-30
US63/325,317 2022-03-30
PCT/US2023/016963 WO2023192514A1 (en) 2022-03-30 2023-03-30 Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2023245728A1 true AU2023245728A1 (en) 2024-09-26

Family

ID=86184900

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023245728A Pending AU2023245728A1 (en) 2022-03-30 2023-03-30 Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof

Country Status (13)

Country Link
US (1) US20240101682A1 (https=)
EP (1) EP4499696A1 (https=)
JP (1) JP2025511135A (https=)
KR (1) KR20240163751A (https=)
CN (1) CN119403831A (https=)
AU (1) AU2023245728A1 (https=)
CA (1) CA3255754A1 (https=)
CL (1) CL2024002899A1 (https=)
CO (1) CO2024014799A2 (https=)
CR (1) CR20240462A (https=)
IL (1) IL315960A (https=)
MX (1) MX2024011978A (https=)
WO (1) WO2023192514A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318499A (en) * 2022-07-30 2025-03-01 Pinetree Therapeutics Inc Compounds for targeted lysosomal degradation and methods of using them
AU2023378712A1 (en) * 2022-11-07 2025-05-01 Pinetree Therapeutics, Inc. Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2017171373A2 (ko) * 2016-03-29 2017-10-05 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
KR102048474B1 (ko) * 2016-03-29 2019-11-26 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
CA3060190A1 (en) * 2017-04-24 2018-11-01 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
WO2020027224A1 (ja) * 2018-07-31 2020-02-06 国立大学法人東京大学 新たな結合特異性を抗体に付与する超汎用法
WO2020079280A1 (en) * 2018-10-19 2020-04-23 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of squamous cell cancers

Also Published As

Publication number Publication date
KR20240163751A (ko) 2024-11-19
CL2024002899A1 (es) 2025-02-07
US20240101682A1 (en) 2024-03-28
CA3255754A1 (en) 2023-10-05
JP2025511135A (ja) 2025-04-15
EP4499696A1 (en) 2025-02-05
WO2023192514A1 (en) 2023-10-05
CO2024014799A2 (es) 2024-11-18
IL315960A (en) 2024-11-01
CN119403831A (zh) 2025-02-07
CR20240462A (es) 2024-12-11
MX2024011978A (es) 2025-02-10

Similar Documents

Publication Publication Date Title
US11155615B2 (en) Anti-ROR1 antibodies
JP2020511993A (ja) ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ−２及びＥｒｂＢ３結合二重特異性抗体
EP3212670A1 (en) Combination therapy for cancer
CN110636861B (zh) 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
US20240101682A1 (en) Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
US20250084178A1 (en) Anti-cd39 antibodies and use thereof
KR20240082379A (ko) 암 치료 방법 및 이의 약제학적 조성물
CA3228576A1 (en) Anti-gdf15 antibodies, compositions and uses thereof
US20250215087A1 (en) Combination therapy of kras inhibitor and treg depleting agent
KR20250044738A (ko) 표적화 라이소좀 분해를 위한 조성물 및 이의 사용 방법
WO2023164872A1 (en) Anti-cd39 antibodies and use thereof
EA052797B1 (ru) Биспецифичные антитела, содержащие домен, связывающий nrp1, и способы их применения
TW201642904A (zh) 含抗ｆｇｆｒ２抗體及其他藥劑之組成物
WO2025029618A1 (en) Non-receptor tyrosine kinase compositions for targeted lysosomal degradaton and methods of use thereof
HK40113788A (zh) 抗cd39抗体及其用途
HK40055726A (en) Anti-ror1 antibodies
HK40019947A (en) Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer